Mainboard listed Q & M Dental Group (Singapore) Limited ("Q & M" or "the Group" and together with its subsidiaries, the "Group") is proud to announce the release of the "Treatment Plan" on its Artificial Intelligence (AI)-module developed by its 49%-owned subsidiary, EM2AI, in collaboration with AI Singapore.
More info..

More info..

Q&M Dental Group Limited is honoured to announce that it has received the prestigious "Best Investor Relations Award (Gold)" at the 18th Singapore Corporate Awards' ceremony held on 7 September 2023. The Award is given in recognition of Q&M Dental Group's commitment to maintaining transparency, communication, and excellence in investor relations.
More info..

Mainboard-listed Q&M Dental Group (Singapore) Limited ("Q&M", the "Company", and together with its subsidiaries, the "Group") today reported total revenue of S$87.1 million, and profit after tax attributable to parent of S$5.3 million for the first half ended 30 June 2023 ("1H2023"). The Group's earnings before interest, tax, depreciation, amortisation ("EBITDA") for 1H2023 was S$18.5 million.
More info..

Q&M Free Dental Clinic Limited, a registered charity under the Commission of Charities, has opened its first Q&M Free Dental Clinic in Chai Chee dedicated to delivering essential dental treatment for underprivileged individuals and families in need.
More info..

Catalist listed Aoxin Q&M Dental Limited, announced on 1 March 2023, a 12.8% lower revenue of RMB139.7 million for full year ended 31 December 2022 (FY2022). The Group reported a net loss after tax excluding impairment loss on investment in our associate of RMB7.3 million for FY2022, primarily due to the number of shutdowns from China's zero-Covid policy that was in place all the way up until 8 January 2023.
More info..

Mainboard-listed Q&M Dental Group (Singapore) Limited today reported total revenue of S$181.2 million, and profit after tax attributable to parent (PATMI) of S$11.3 million for the twelve months ended 31 December 2022 (FY2022). The Group Earnings before interest, tax, depreciation, amortisation (EBITDA) for FY2022 was S$35.2 million.
More info..

Mainboard-listed Q&M Dental Group (Singapore) Limited announced on 29 September 2022 the award of 2,014,245 shares to 7 promising next-generation dentists as part of the Q&M Performance Share Plan (PSP) 2018, as well as the proposed placement of an additional 4,985,755 treasury shares, totalling S$1.75 million, through placement to the same dentists.
More info..

Q&M Dental Group (Singapore) Limited, a leading private dental healthcare group in Asia, reported net profit excluding other gains or losses attributable to shareholders of S$7.2 million for the quarter ended 31 March 2022 (1Q2022) compared to S$5.8 million in the corresponding period (1Q2021).
More info..

Q&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group"), a leading private dental healthcare group in Asia, today reported the highest-ever revenue and profit after tax of S$205.6 million and S$39.4 million respectively for the financial year ended 31 December 2021 ("FY2021").
More info..

Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) Limited ("Q&M Dental") and 49% owned by Aoxin Q&M Dental Group Limited ("Aoxin Q&M Dental"), today announced that it has been granted a license by the Ministry of Health, Singapore to provide offsite COVID-19 polymerase chain reaction ("PCR") swab services and serology sample collection.
More info..

Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.
More info..

Q&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group"), a leading private dental healthcare group in Asia, today reported net profit after tax attributable to shareholders of S$27.3 million for the nine months ended 30 September 2021 ("9M2021"), and net profit after tax attributable to shareholders S$9.5 million for the three months ended 30 September 2021 ("3Q2021").
More info..